Filing excerpt
Regeneron currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“GAAP”) and its non-GAAP financial results for the third quarter 2026 will include an acquired in-process research and development (“IPR&D”) charge of approximately $22 million on a pre-tax basis.